Gennova Pharma makes India's first

Pune-based pharmaceutical manufacturer Gennova Biopharmaceuticals Ltd has started developing an Omnicron specific vaccine, which is hailed as India's first "strain-specific" vaccine. The company is almost done with the phase 3 trials of its Covid-19. This mRNA vaccine's efficacy is being promulgated as a barrier against the Omicron variant. However, the tests for safety and efficacy in humans are still under process.

Messenger RNA or mRNA technology involves the injection of a small part of the virus’s genetic code (RNA) to stimulate the recipient’s immune response. It contains instructions for human cells to make proteins that mimic part of the novel coronavirus, spurring the immune system into action. No actual virus is contained in these vaccines.